Welcome!

News Feed Item

Stammering Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stammering Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280948/Stammering-Global-Clinical-Trials-Review-H2-2014.html

Stammering Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Stammering Global Clinical Trials Review, H2, 2014" provides data on the Stammering clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Stammering. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Stammering. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Stammering 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Stammering to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Stammering to Central Nervous System Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Stammering 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Clinical Trial Profiles 25
Clinical Trial Overview of Top Companies 25
Endo International plc 25
Clinical Trial Overview of Endo International plc 25
Clinical Trial Overview of Top Institutes / Government 26
National Institute on Deafness and Other Communication Disorders 26
Clinical Trial Overview of National Institute on Deafness and Other Communication Disorders 26
National Institute of Neurological Disorders and Stroke 27
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 27
The University of Sydney 28
Clinical Trial Overview of The University of Sydney 28
Tbilisi State Medical University 29
Clinical Trial Overview of Tbilisi State Medical University 29
Universidade Federal de Minas Gerais 30
Clinical Trial Overview of Universidade Federal de Minas Gerais 30
Pharmacology Research Institute 31
Clinical Trial Overview of Pharmacology Research Institute 31
The Newcastle upon Tyne Hospitals NHS Foundation Trust 32
Clinical Trial Overview of The Newcastle upon Tyne Hospitals NHS Foundation Trust 32
Universitatsklinikum Munster 33
Clinical Trial Overview of Universitatsklinikum Munster 33
University of California, Irvine 34
Clinical Trial Overview of University of California, Irvine 34
Five Key Clinical Profiles 35
Appendix 50
Abbreviations 50
Definitions 50
Research Methodology 51
Secondary Research 51
About GlobalData 52
Contact Us 52
Disclaimer 52
Source 52

List of Tables

Stammering Therapeutics, Global, Clinical Trials by Region, 2014* 6
Stammering Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Stammering Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Stammering Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Stammering Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Stammering Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Stammering Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Stammering to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Stammering Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Stammering Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Stammering to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Stammering Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Stammering Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Stammering Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Stammering Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Stammering Therapeutics, Global, Suspended Clinical Trials, 2014* 21
Stammering Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Stammering Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Stammering Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Endo International plc, 2014* 25
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute on Deafness and Other Communication Disorders, 2014* 26
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 27
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Sydney, 2014* 28
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Tbilisi State Medical University, 2014* 29
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Universidade Federal de Minas Gerais, 2014* 30
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacology Research Institute, 2014* 31
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by The Newcastle upon Tyne Hospitals NHS Foundation Trust, 2014* 32
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitatsklinikum Munster, 2014* 33
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2014* 34

List of Figures

Stammering Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Stammering Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Stammering Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Stammering Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 10
Stammering Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Stammering to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Stammering Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Stammering Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Stammering to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Stammering Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Stammering Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Stammering Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Stammering Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Stammering Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
GlobalData Methodology 51

To order this report: Stammering Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280948/Stammering-Global-Clinical-Trials-Review-H2-2014.html

_________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
IoT is fundamentally transforming the auto industry, turning the vehicle into a hub for connected services, including safety, infotainment and usage-based insurance. Auto manufacturers – and businesses across all verticals – have built an entire ecosystem around the Connected Car, creating new customer touch points and revenue streams. In his session at @ThingsExpo, Macario Namie, Head of IoT Strategy at Cisco Jasper, will share real-world examples of how IoT transforms the car from a static p...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
From wearable activity trackers to fantasy e-sports, data and technology are transforming the way athletes train for the game and fans engage with their teams. In his session at @ThingsExpo, will present key data findings from leading sports organizations San Francisco 49ers, Orlando Magic NBA team. By utilizing data analytics these sports orgs have recognized new revenue streams, doubled its fan base and streamlined costs at its stadiums. John Paul is the CEO and Founder of VenueNext. Prior ...
One of biggest questions about Big Data is “How do we harness all that information for business use quickly and effectively?” Geographic Information Systems (GIS) or spatial technology is about more than making maps, but adding critical context and meaning to data of all types, coming from all different channels – even sensors. In his session at @ThingsExpo, William (Bill) Meehan, director of utility solutions for Esri, will take a closer look at the current state of spatial technology and ar...
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, will discuss the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports. The session will include a working demo and a technical d...
Businesses are struggling to manage the information flow and interactions between all of these new devices and things jumping on their network, and the apps and IT systems they control. The data businesses gather is only helpful if they can do something with it. In his session at @ThingsExpo, Chris Witeck, Principal Technology Strategist at Citrix, will discuss how different the impact of IoT will be for large businesses, expanding how IoT will allow large organizations to make their legacy ap...
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the protocols that communicate data and the emerging data analy...
As ridesharing competitors and enhanced services increase, notable changes are occurring in the transportation model. Despite the cost-effective means and flexibility of ridesharing, both drivers and users will need to be aware of the connected environment and how it will impact the ridesharing experience. In his session at @ThingsExpo, Timothy Evavold, Executive Director Automotive at Covisint, will discuss key challenges and solutions to powering a ride sharing and/or multimodal model in the a...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management solutions, helping companies worldwide activate their data to drive more value and business insight and to transform moder...
Creating replica copies to tolerate a certain number of failures is easy, but very expensive at cloud-scale. Conventional RAID has lower overhead, but it is limited in the number of failures it can tolerate. And the management is like herding cats (overseeing capacity, rebuilds, migrations, and degraded performance). Download Slide Deck: ▸ Here In his general session at 18th Cloud Expo, Scott Cleland, Senior Director of Product Marketing for the HGST Cloud Infrastructure Business Unit, discusse...
Whether they’re located in a public, private, or hybrid cloud environment, cloud technologies are constantly evolving. While the innovation is exciting, the end mission of delivering business value and rapidly producing incremental product features is paramount. In his session at @DevOpsSummit at 19th Cloud Expo, Kiran Chitturi, CTO Architect at Sungard AS, will discuss DevOps culture, its evolution of frameworks and technologies, and how it is achieving maturity. He will also cover various st...
SYS-CON Events announced today that eCube Systems, a leading provider of middleware modernization, integration, and management solutions, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. eCube Systems offers a family of middleware evolution products and services that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of So...
Digital innovation is the next big wave of business transformation based on digital technologies of which IoT and Big Data are key components, For example: Business boundary innovation is a challenge to excavate third-party business value using IoT and BigData, like Nest Business structure innovation may propose re-building business structure from scratch, as Uber does in the taxicab industry The social model innovation is also a big challenge to the new social architecture with the design fr...